Polaris Group (6550) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Polaris Group TWD 9.86, price TWD 16.75, upside -41.1%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Polaris Group, together with its subsidiaries, offers biotechnology, pharmaceutical testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It also offers healthcare consulting, staffing, and MDS solutions.
Show more
Polaris Group, together with its subsidiaries, offers biotechnology, pharmaceutical testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It also offers healthcare consulting, staffing, and MDS solutions. The company was incorporated in 2006 and is based in Grand Cayman, Cayman Islands.
Stock analysis
Polaris Group (6550) currently trades at 16.75 TWD, while our model-based Fair Value estimate is 9.86 TWD, 41.1% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: 6.68 TWD (bear) to 12.40 TWD (bull), the price of 16.75 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Polaris Group reported revenue of 40.6M TWD in FY2025 versus 15.0M TWD in FY2021, a compound +28.2%/yr. Reported net income was −3.9B TWD in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).
What moves the price
The share trades about 76% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −41%, 6550 screens richer than that median.
Fair Value models
Bear 6.68 TWDFair Value 9.86 TWDBull 12.40 TWD
Price 16.75 TWD · Upside -41.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.32/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−62.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+84.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.0%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−7,205.1% (2020) → −7,089.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 605 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score36 · Below median
Fair Value upside−41.1% · Above median
Profitability
Return on assets−20.4% · Below median
Growth and dividend
Revenue growth−15.6% · Bottom 25%
Balance sheet
Debt / equity0.40× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.05× · Cheapest 25%
P/S (TTM)3.52× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)80· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Polaris Group Fair Value". https://www.fairvalue-calculator.com/stock/6550
Frequently asked questions
Is Polaris Group (6550) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of 9.86 TWD versus a price of 16.75 TWD, about −41% upside (overvalued).
What is the fair value of 6550?
Our model-based fair value for Polaris Group is 9.86 TWD (as of Oct 4, 2026), built from audited fundamentals. The current price: 16.75 TWD.
What is the quality score of 6550?
Polaris Group has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Polaris Group (6550)?
Our model-based price target is the fair value of 9.86 TWD (as of Oct 4, 2026) from 1 valuation models. Cautious scenario 6.68 TWD, optimistic scenario 12.40 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Polaris Group stock forecast for 2026?
Our models put fair value at 9.86 TWD, about −41% upside versus a price of 16.75 TWD (overvalued). Cautious scenario 6.68 TWD, optimistic scenario 12.40 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Polaris Group (6550)?
Polaris Group reported trailing-twelve-month revenue of about 68.0M TWD (latest available figure, as of Oct 4, 2026).
What is the intrinsic value of Polaris Group (6550)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Polaris Group it is 9.86 TWD per share (as of Oct 4, 2026), against a price of 16.75 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Polaris Group stock overvalued or undervalued in 2026?
As of Oct 4, 2026, 6550 trades above its calculated fair value: price 16.75 TWD, fair value 9.86 TWD, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6550?
No. The price is what the market pays today (16.75 TWD); the fair value is what the company's own numbers justify (9.86 TWD). For Polaris Group the two are 6.89 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Polaris Group worth?
The market values Polaris Group at about 7.6B TWD (market capitalisation, as of Oct 4, 2026). Per share that is 16.75 TWD; our models calculate a fair value of 9.86 TWD per share.
What do the bullish and bearish scenarios say about 6550?
Our models span a range for Polaris Group: cautious scenario 6.68 TWD, base 9.86 TWD, optimistic 12.40 TWD per share (as of Oct 4, 2026, price 16.75 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Polaris Group (6550)?
Balance-sheet figures for Polaris Group (as of Oct 4, 2026): return on equity −81.1%, debt of 0.40 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is 6550 from its 52-week high?
Polaris Group trades at 16.75 TWD, about 76% below its 52-week high of 70.84 TWD and at the low of 16.75 TWD (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 9.86 TWD is for.
Which stocks are comparable to Polaris Group?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Polaris Group stock attractive at the current price?
The data as of Oct 4, 2026: price 16.75 TWD, calculated fair value 9.86 TWD (−41%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6550 calculated?
We run Polaris Group through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 9.86 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Polaris Group itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Polaris Group (6550)?
The closing price on Oct 2, 2026 was 16.75 TWD. Our model-based fair value is 9.86 TWD, about −41% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Polaris Group right now?
The price sits above even our optimistic bull case (12.40 TWD). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (6.68 TWD to 12.40 TWD) leaves room in how you read the outcome.
Key figures of Polaris Group
How large is the market capitalisation of Polaris Group (6550)?
The market capitalisation of Polaris Group is 7.6B TWD (≈ $239M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Polaris Group (6550)?
Earnings per share at Polaris Group are −9.05 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Polaris Group (6550)?
The return on equity (ROE) of Polaris Group is −81.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Polaris Group (6550)?
On an EBIT basis the return on assets of Polaris Group is −21.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Polaris Group (6550)?
The operating margin of Polaris Group is −7,429% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Polaris Group (6550)?
Revenue at Polaris Group is growing −15.6% versus a year earlier (3y avg +84.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Polaris Group (6550) generate?
The free cash flow of Polaris Group is −3.2B TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Polaris Group (6550) carry?
The net debt of Polaris Group is 517M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Polaris Group in the live analysis
One click puts Polaris Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
